osimertinib相关论文
表皮生长因子受体（EGFR）基因作为重要的肿瘤驱动基因，在非小细胞肺癌（NSCLC）的发生、发展中发挥着重要作用。奥希替尼作为最新一代的EGF......
Evaluation of EGFR T790M Mutation Detection with a CODAR-ARMS PCR Assay Using Nucleic Acids Extracte
...
Survivals in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs followed by
...
Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell
Osimertinib(OSI),also known as AZD9291,is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor ......
Treatment of osimertinib(AZD9291)-resistant non-small cell lung cancer HCC-827/OSIR cells by targeti
Objective: The third generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)osimertinib(OSI,also......
Treatment of osimertinib(AZD9291)-resistant non-small cell lung cancer HCC-827/OSIR cells by targeti
Objective: The third generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)osimertinib(OSI,also......
Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-smal
BACKGROUND Toxic epidermal necrolysis and Stevens-Johnson syndrome are acute lifethreatening skin reactions.AZD9291 has ......
Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benef
BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have been adopted as the standard of ca......
Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A ca
BACKGROUND Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor(......
第1,2代表皮生长因子受体酪氨酸激酶抑制药(EGFR-TKIs)可用于表皮生长因子受体(EGFR)基因敏感突变的非小细胞肺癌(NSCLC)患者的一......
目的:探讨肺癌脑转移继发癫(疒间)病人在进行靶向及抗癫(疒间)治疗时的用药选择.方法:围绕1例肺癌脑转移继发癫(疒间)病人的临床资......
Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small
The third-generation of epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs),represented by osimertini......
Glioblastoma(GBM)patients have extremely poor prognoses,and currently no effective treatment available including surgery......
,Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cance
Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that......
Final Overall Survival Results from the FLAURA Trial: a Phase Ⅲ Study on Osimertinib in EGFR-Mutated
The discovery of activating mutations in epidermal growth factor receptor (EGFR) and development of first-/second-genera......
Separation, Identification, Isolation and Characterization of Degradation Product of Osimertinib Tab
<span style="font-family:Verdana;">The present work encompasses identification and characterization of major degradation......
目的探讨奥希替尼治疗T790M突变阳性晚期非小细胞肺癌(NSCLC)患者的疗效及预后。方法将90例T790M突变阳性晚期NSCLC患者按治疗方法......
目的:探讨埃索美拉唑对奥希替尼在大鼠体内药动学的影响。方法:将12只大鼠随机分两组,一组给予超纯水,另一组给予埃索美拉唑溶液(1......
目的研究奥西替尼脂质体治疗NSCLC小鼠的疗效及对其免疫功能、生存时间的影响。方法将SCID小鼠随机分为6组:正常组,模型组,低、高......
目的探究奥希替尼在治疗表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-......
目的比较手术和非手术治疗肺腺癌并四肢长骨转移T790M基因突变阳性患者的临床疗效。方法选择2016年7月-2018年12月在海南省东方市......
背景与目的:表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)在治疗......
奥希替尼作为第三代表皮生长因子受体酪氨酸激酶抑制剂,对表皮生长因子受体(EGFR)T790M突变型肺腺癌有显著疗效。随着临床研究的深......
报道1例晚期肺腺癌患者奥希替尼治疗后耐药,基因检测示EGFR 19del/T790M/顺式C797S突变,联合使用奥希替尼、培美曲塞、贝伐珠单抗......
目的:建立反相高效液相色谱法测定奥斯替尼含量的方法。方法:采用Diamonsil C18色谱柱（4.6 mm×150mm,5μm）,流动相为水-乙腈,梯度洗......
osimertinib是一种口服的、不可逆的、具有T790M突变基因选择性的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)。2015年11月osimer......
期刊
本文通过Osimertinib原研路线,分析总结了B法和C法两种合成路线,两种路线各有优劣,可通过进一步优化工艺路线适用于工业化生产。......
目的:非小细胞肺癌是全球癌症相关死亡的主要原因之一。基于铂类的化疗组合方案给非小细胞肺癌及转移癌患者提供了一个有效的治疗......
学位
目的研究Osimertinib联合二甲双胍对吉非替尼获得性耐药的非小细胞肺癌PC 9/GR细胞的生长抑制效应及其可能机制。方法 Osimertinib......
期刊
